Matches in DBpedia 2016-04 for { ?s ?p "Rilpivirine (TMC278, trade name Edurant) is a pharmaceutical drug, developed by Tibotec, for the treatment of HIV infection. It is a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) with higher potency, longer half-life and reduced side-effect profile compared with older NNRTIs, such as efavirenz.Rilpivirine entered phase III clinical trials in April 2008, and was approved for use in the United States in May 2011."@en }
Showing triples 1 to 2 of
2
with 100 triples per page.
- Rilpivirine comment "Rilpivirine (TMC278, trade name Edurant) is a pharmaceutical drug, developed by Tibotec, for the treatment of HIV infection. It is a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) with higher potency, longer half-life and reduced side-effect profile compared with older NNRTIs, such as efavirenz.Rilpivirine entered phase III clinical trials in April 2008, and was approved for use in the United States in May 2011.".
- Q421547 comment "Rilpivirine (TMC278, trade name Edurant) is a pharmaceutical drug, developed by Tibotec, for the treatment of HIV infection. It is a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) with higher potency, longer half-life and reduced side-effect profile compared with older NNRTIs, such as efavirenz.Rilpivirine entered phase III clinical trials in April 2008, and was approved for use in the United States in May 2011.".